Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **glutamate neurotransmitter synthesis pathway** refers to the biochemical processes by which glutamate, the brain’s primary excitatory neurotransmitter, is synthesized, recycled, and maintained within the central nervous system. Glutamate is predominantly produced in presynaptic neurons from the precursor **glutamine** via the mitochondrial enzyme **glutaminase**[1][2][4]. Glutamine is originally supplied by astrocytes through the action of glutamine synthetase, unique to these glial cells[3][6]. This cooperation forms the **glutamate–glutamine cycle**, essential for recycling neurotransmitter pools and for rapidly terminating glutamate action in the synapse[1][2][3][4]. Within neurons, glutamate is packaged into synaptic vesicles by **vesicular glutamate transporters (VGLUTs)**[1][2]. After release, glutamate is swiftly cleared from the synaptic cleft by sodium-dependent **excitatory amino acid transporters (EAATs)**, present on both neurons and astrocytes. In glial cells, glutamate is converted back to glutamine by **glutamine synthetase**, which is then sent back to neurons for continued neurotransmitter production[1][2][3][6][7]. Disruption of this tightly regulated pathway, especially dysregulation of synaptic glutamate concentration, is linked to several pathologies due to **excitotoxicity**, including ALS, epilepsy, and acute brain injuries[5]. Although components of this pathway (such as glutaminase, glutamine synthetase, and the various transporters) can be considered drug targets, **the pathway itself is not a discrete molecular target but a collection of metabolic and transport steps**, so “Glutamate neurotransmitter synthesis pathway” should not be considered a canonical therapeutic target[1][2][3][4][5][6][7]. **Summary of correctness**: This term refers to a biological pathway rather than a single molecule, receptor, or drug target, so **it is not a canonical therapeutic target** but a description of key biochemical processes involving multiple enzymes and transporters[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate neurotransmitter synthesis pathway.